BATS:HELX Franklin Genomic Advancements ETF (HELX) Price, Holdings, & News $39.49 0.00 (0.00%) As of 07/14/2026 04:10 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHoldingsOwnershipRatingsBuy This Stock About Franklin Genomic Advancements ETF (BATS:HELX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get HELX alerts:Sign Up Key Stats Today's Range$39.42▼$39.8850-Day Range$32.53▼$41.1652-Week Range$26.99▼$41.30Volume4,777 shsAverage Volume1,425 shsMarket Capitalization$15.80 millionAssets Under Management$29.59 millionDividend YieldN/ANet Expense Ratio0.50%Aggregate RatingModerate Buy ETF Overview The Franklin Genomic Advancements ETF (HELX) is an exchange-traded fund that is based on the Solactive Genomics index. The fund is an actively managed portfolio of global equity securities of companies relevant to genomic discovery. HELX was launched on Feb 25, 2020 and is managed by Franklin Templeton. Read More Franklin Genomic Advancements ETF ExpensesTypeHELXTheme ETFsEquity ETFsBATS ETFsAll ETFsManagement Fee0.50%0.57%0.57%0.59%0.53%Other Expenses0.00%0.58%0.55%0.46%0.55%Total Expense0.50%0.74%0.76%0.72%0.73%Fee Waiver0.00%-0.75%-0.64%-0.41%-0.62%Net Expense0.50%0.60%0.63%0.66%0.60% Receive HELX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Franklin Genomic Advancements ETF and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HELX ETF News HeadlinesFranklin Genomic Advancements ETF - Markets InsiderJuly 23, 2025 | markets.businessinsider.comFranklin Emerging Markets UCITS ETF (FLXE)September 18, 2024 | investing.comThe window is closingWe printed 1,000 copies of this report and 688 are gone—when the last one goes out, we're pulling it offline because the information inside is too sensitive to leave up indefinitely. Inside the remaining copies is the executive order Trump can sign tomorrow, the same legal authority FDR used in 1934 to move billions in wealth overnight, and exactly how to position before it happens.July 15 at 1:00 AM | American Alternative (Ad)Franklin Ethereum ETF (EZET)August 2, 2024 | finance.yahoo.comChainlink Integration Enhances Transparency for 21Shares’ Ether ETFJuly 30, 2024 | msn.comFranklin Catholic Princ Em Sov Ucits Etf Share Price (CATHEM.MI)April 23, 2024 | lse.co.ukSee More Headlines HELX ETF - Frequently Asked Questions How have HELX shares performed this year? Franklin Genomic Advancements ETF's stock was trading at $36.35 at the beginning of 2026. Since then, HELX stock has increased by 8.6% and is now trading at $39.49. How do I buy shares of Franklin Genomic Advancements ETF? Shares of HELX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Franklin Genomic Advancements ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that Franklin Genomic Advancements ETF investors own include Merck & Co., Inc. (MRK), iShares iBonds Dec 2025 Term Muni Bond ETF (IBMN), Novavax (NVAX) and AbbVie (ABBV). Fund Details IssuerFranklin Templeton Investments Fund NameFranklin Genomic Advancements ETF Tax ClassificationRegulated Investment Company Stock ExchangeBATSCurrent SymbolBATS:HELX Inception Date2/25/2020 Fund ManagerMatthew J.Moberg, Joyce Lin WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkN/A CategoryStrategy FocusTheme Development LevelBlended Development RegionGlobal Number of Holdings66 Fund Statistics Assets Under Management$29.59 million Average Daily Volume$0.00 Discount/Premium0.05% Administrator, Advisor and Custodian AdministratorFranklin Templeton Services, LLC AdvisorFranklin Advisers, Inc. CustodianThe Bank of New York Mellon Corporation DistributorFranklin Templeton Distributors, Inc. Transfer AgentThe Bank of New York Mellon Corporation TrusteeN/A Lead Market MakerCitadel Options OptionableOptionable Options Volume1 Put Options0 Call Options1 Miscellaneous Outstanding Shares400,000Beta1.05 Creation Unit50,000 Creation Fee$200.00 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report Top 10 HELX HoldingsGuardant Health (NASDAQ:GH)Holding Weight: 9.90%Natera (NASDAQ:NTRA)Holding Weight: 7.47%Krystal Biotech (NASDAQ:KRYS)Holding Weight: 6.21%Ligand Pharmaceuticals (NASDAQ:LGND)Holding Weight: 4.55%Adaptive Biotechnologies (NASDAQ:ADPT)Holding Weight: 3.83%BridgeBio Pharma (NASDAQ:BBIO)Holding Weight: 3.53%United Therapeutics (NASDAQ:UTHR)Holding Weight: 3.50%Eli Lilly and Company (NYSE:LLY)Holding Weight: 2.91%Vertex Pharmaceuticals (NASDAQ:VRTX)Holding Weight: 2.84%AstraZeneca PLCHolding Weight: 2.70%Full Holdings DetailsHELX Sector ExposureHELX Industry Exposure This page (BATS:HELX) was last updated on 7/15/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Franklin Genomic Advancements ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Franklin Genomic Advancements ETF With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
